Compare HLLY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | BCYC |
|---|---|---|
| Founded | 1903 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.2M | 476.6M |
| IPO Year | N/A | 2019 |
| Metric | HLLY | BCYC |
|---|---|---|
| Price | $4.11 | $7.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $4.43 | ★ $18.73 |
| AVG Volume (30 Days) | ★ 701.9K | 237.4K |
| Earning Date | 03-10-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $598,132,000.00 | $28,339,000.00 |
| Revenue This Year | $1.75 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $6.03 |
| 52 Week High | $4.43 | $13.66 |
| Indicator | HLLY | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 53.83 |
| Support Level | $4.03 | $6.37 |
| Resistance Level | $4.27 | $7.34 |
| Average True Range (ATR) | 0.17 | 0.33 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 40.82 | 68.27 |
Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.